EMA: PRAC recommends further measures to minimise risk of osteonecrosis of the jaw with bisphosphonate medicine

European Medicines Agency\'s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a periodic review of one of the bisphosphonate medicines with a known risk of osteonecrosis of the jaw, Aclasta (zoledronic acid). The PRAC recommended a number of measures, including an update to the product information and the introduction of a patient reminder card, to minimise the known risk of osteonecrosis (death of bone tissue) of the jaw.

kapitał ludzki

fundusz społeczny

Narodowe Centrum Badań i Rozwoju

innowacyjna gospodarka

rozwój regionalny